These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 28264880)
1. Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. Moutinho M; Landreth GE J Lipid Res; 2017 Oct; 58(10):1937-1949. PubMed ID: 28264880 [TBL] [Abstract][Full Text] [Related]
2. Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. Casali BT; Corona AW; Mariani MM; Karlo JC; Ghosal K; Landreth GE J Neurosci; 2015 Jun; 35(24):9173-81. PubMed ID: 26085639 [TBL] [Abstract][Full Text] [Related]
3. Nuclear receptors as therapeutic targets for Alzheimer's disease. Mandrekar-Colucci S; Landreth GE Expert Opin Ther Targets; 2011 Sep; 15(9):1085-97. PubMed ID: 21718217 [TBL] [Abstract][Full Text] [Related]
4. Type II nuclear receptors with potential role in Alzheimer disease. Jonathan MC; Adrián SH; Gonzalo A Mol Aspects Med; 2021 Apr; 78():100940. PubMed ID: 33397589 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. Yan Q; Zhang J; Liu H; Babu-Khan S; Vassar R; Biere AL; Citron M; Landreth G J Neurosci; 2003 Aug; 23(20):7504-9. PubMed ID: 12930788 [TBL] [Abstract][Full Text] [Related]
6. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease. Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544 [TBL] [Abstract][Full Text] [Related]
7. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Landreth G; Jiang Q; Mandrekar S; Heneka M Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459 [TBL] [Abstract][Full Text] [Related]
9. Small molecule TBTC as a new selective retinoid X receptor α agonist improves behavioral deficit in Alzheimer's disease model mice. Sun Y; Fan J; Zhu Z; Guo X; Zhou T; Duan W; Shen X Eur J Pharmacol; 2015 Sep; 762():202-13. PubMed ID: 26026644 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368 [TBL] [Abstract][Full Text] [Related]
14. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders. Wójtowicz S; Strosznajder AK; Jeżyna M; Strosznajder JB Neurochem Res; 2020 May; 45(5):972-988. PubMed ID: 32170673 [TBL] [Abstract][Full Text] [Related]
17. Regulation of Oligodendrocyte Differentiation and Myelination by Nuclear Receptors: Role in Neurodegenerative Disorders. Sandoval-Hernández A; Contreras MJ; Jaramillo J; Arboleda G Adv Exp Med Biol; 2016; 949():287-310. PubMed ID: 27714695 [TBL] [Abstract][Full Text] [Related]